Iodine-123 is produced in a cyclotron by proton irradiation of xenon in a capsule. Xenon-124 absorbs a proton and immediately loses a neutron and proton to form xenon-123, or else loses two neutrons to form caesium-123, which decays to xenon-123. The xenon-123 formed by either route then decays to iodine-123, and is trapped on the inner wall of the irradiation capsule under refrigeration, then eluted with sodium hydroxide in a halogen disproportionation reaction, similar to collection of iodine-125 after it is formed from xenon by neutron irradiation. Iodine-123 is usually supplied as -sodium iodide in 0.1 M sodium hydroxide solution, at 99.8% isotopic purity. 123I for medical applications has also been produced at Oak Ridge National Laboratory by proton cyclotron bombardment of 80% isotopically enriched tellurium-123.
Decay
The detailed decay mechanism is electron capture to form an excited state of the nearly-stable nuclide tellurium-123. This excited state of 123Te produced is not the metastablenuclear isomer123mTe, but rather is a lower-energy nuclear isomer of 123Te that immediately gamma decays to ground state123Te at the energies noted, or else decays by internal conversion electron emission, followed by an average of 11 Auger electrons emitted at very low energies. The latter decay channel also produces ground-state 123Te. Especially because of the internal conversion decay channel, 123I is not an absolutely pure gamma-emitter, although it is sometimes clinically assumed to be one. The Auger electrons from the radioisotope have been found in one study to do little cellular damage, unless the radionuclide is directly incorporated chemically into cellular DNA, which is not the case for present radiopharmaceuticals which use 123I as the radioactive label nuclide. The damage from the more penetrating gamma radiation and 127 keV internal conversion electron radiation from the initial decay of 123Te is moderated by the relatively short half-life of the isotope.
Medical applications
123I is the most suitable isotope of iodine for the diagnostic study of thyroid diseases. The half-life of approximately 13.13 hours is ideal for the 24-hour iodine uptake test and 123I has other advantages for diagnostic imaging thyroid tissue and thyroid cancermetastasis. The energy of the photon, 159 keV, is ideal for the NaI crystal detector of current gamma cameras and also for the pinhole collimators. It has much greater photon flux than 131I. It gives approximately 20 times the counting rate of 131I for the same administered dose. The radiation burden to the thyroid is far less than that of 131I. Moreover, scanning a thyroid remnant or metastasis with 123I does not cause "stunning" of the tissue, because of the low radiation burden of this isotope. For the same reasons, 123I is never used for thyroid cancer or Graves diseasetreatment, and this role is reserved for 131I. 123I is supplied as sodium iodide, sometimes in basic solution in which it has been dissolved as the free element. This is administered to a patient by ingestion under capsule form, by intravenous injection, or in a drink. The iodine is taken up by the thyroid gland and a gamma camera is used to obtain functional images of the thyroid for diagnosis. Quantitative measurements of the thyroid can be performed to calculate the iodine uptake for the diagnosis of hyperthyroidism and hypothyroidism. Dosing can vary; is recommended for thyroid imaging and for total body while an uptake test may use. There is a study that indicates a given dose can effectively result in effects of an otherwise higher dose, due to impurities in the preparation. The dose of radioiodine 123I is typically tolerated by individuals who cannot tolerate contrast mediums containing larger concentration of stable iodine such as used in CT scan, intravenous pyelogram and similar imaging diagnostic procedures. Iodine is not an allergen. , gastric and oral mucosa, salivary glands, arterial walls, ovary and thymus. In the thyroid gland, I-concentration is more progressive, as in a reservoir. 123I is also used as a label in other imaging radiopharmaceuticals e.g.metaiodobenzylguanidine and ioflupane.
Precautions
Removal of radioiodine contamination can be difficult and use of a decontaminant specially made for radioactive iodine removal is advised. Two common products designed for institutional use are Bind-It and I-Bind. General purpose radioactive decontamination products are often unusable for iodine, as these may only spread or volatilize it.
